ストックスクリーナーアプリを入手
89.30
0.31%
0.28
アフターアワーズ：
89.32
0.02
+0.02%
前日終値:
$89.02
開ける：
$88.55
24時間の取引高:
1.22M
Relative Volume:
0.73
時価総額：
$44.00B
収益：
$9.93B
当期純損益:
$1.12B
株価収益率:
39.69
EPS:
2.25
ネットキャッシュフロー:
$1.58B
1週間 パフォーマンス:
+1.98%
1か月 パフォーマンス:
+4.85%
6か月 パフォーマンス:
+7.01%
1年 パフォーマンス:
+0.57%
1日の値動き範囲:
$88.55
$89.51
1週間の範囲:
$86.94
$89.52
52週間の値動き範囲:
$80.48
$101.10
Alcon Inc Stock (ALC) Company Profile
ALC を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
89.30 | 44.00B | 9.93B | 1.12B | 1.58B | 2.25 |
|
ISRG
Intuitive Surgical Inc
|
540.60 | 189.82B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
177.27 | 49.98B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
255.88 | 37.05B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
221.22 | 16.36B | 2.90B | 467.20M | 306.90M | 6.37 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-05-20 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2025-05-14 | 繰り返されました | BTIG Research | Buy |
| 2025-03-28 | 繰り返されました | Needham | Buy |
| 2025-03-25 | アップグレード | BofA Securities | Neutral → Buy |
| 2025-01-24 | 繰り返されました | Needham | Buy |
| 2025-01-10 | アップグレード | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | 繰り返されました | Needham | Buy |
| 2024-11-12 | 繰り返されました | Needham | Buy |
| 2024-10-10 | アップグレード | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | アップグレード | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | アップグレード | Oppenheimer | Perform → Outperform |
| 2024-04-10 | 開始されました | Goldman | Buy |
| 2024-03-14 | 開始されました | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | 再開されました | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | 開始されました | Bernstein | Outperform |
| 2023-12-18 | ダウングレード | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | 開始されました | Stifel | Buy |
| 2023-12-04 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | アップグレード | JP Morgan | Neutral → Overweight |
| 2023-05-30 | 再開されました | Morgan Stanley | Equal-Weight |
| 2023-05-10 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | アップグレード | Societe Generale | Sell → Hold |
| 2022-12-22 | 開始されました | Mizuho | Buy |
| 2022-11-17 | ダウングレード | Societe Generale | Hold → Sell |
| 2022-08-11 | ダウングレード | Societe Generale | Buy → Hold |
| 2022-05-13 | 再開されました | Credit Suisse | Outperform |
| 2022-05-12 | アップグレード | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | 開始されました | Needham | Buy |
| 2022-03-11 | 開始されました | BofA Securities | Buy |
| 2022-01-18 | ダウングレード | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | 開始されました | Oppenheimer | Perform |
| 2021-07-14 | 開始されました | Deutsche Bank | Buy |
| 2021-05-06 | アップグレード | Citigroup | Sell → Neutral |
| 2021-03-22 | アップグレード | BTIG Research | Neutral → Buy |
| 2020-11-12 | ダウングレード | Guggenheim | Buy → Neutral |
| 2020-07-06 | ダウングレード | Citigroup | Neutral → Sell |
| 2020-07-06 | 開始されました | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-04-08 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | アップグレード | Argus | Hold → Buy |
| 2020-03-24 | アップグレード | Societe Generale | Sell → Hold |
| 2020-03-13 | アップグレード | UBS | Neutral → Buy |
| 2020-03-05 | 開始されました | Citigroup | Neutral |
| 2020-02-26 | アップグレード | Berenberg | Hold → Buy |
| 2020-01-08 | 開始されました | Argus | Hold |
| 2019-10-29 | 開始されました | Stephens | Equal-Weight |
| 2019-08-21 | 繰り返されました | BofA/Merrill | Neutral |
| 2019-06-24 | 開始されました | SVB Leerink | Mkt Perform |
| 2019-06-14 | 開始されました | BTIG Research | Neutral |
| 2019-05-10 | 開始されました | Robert W. Baird | Outperform |
| 2019-05-02 | 開始されました | Credit Suisse | Outperform |
すべてを表示
Alcon Inc (ALC) 最新ニュース
Alcon and Merit Medical: Creating Regulatory and Quality Business Value with AI - Veeva
Should Weakness in Alcon Inc.'s (VTX:ALC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - simplywall.st
Alcon Gets First FDA Approval Since Novartis Spinoff - Orange County Business Journal
Alcon’s Tryptyr Adds Growth, But Valuation Keeps Shares On 'Hold' (NYSE:ALC) - Seeking Alpha
Alcon Stock Rated Buy by BTIG Following TRYPTYR Approval - MSN
Phacoemulsification Devices Market Is Booming Worldwide - openPR.com
Alcon: Achieving UDI Compliance with Veeva RIM - Veeva
Alcon (ALC) Receives Increased Price Target from Citi | ALC Stoc - GuruFocus
Alcon (ALC) Receives Increased Price Target from Citi | ALC Stock News - GuruFocus
Citi more constructive on EU MedTech: Upgrades Demant; Alcon top pick - Investing.com Canada
Alcon Inc. (ALC)’s TRYPTYR Wins FDA Nod for Dry Eye Disease - MSN
BofA Securities lowers Alcon stock price target after Q1 results By Investing.com - Investing.com South Africa
BofA Securities lowers Alcon stock price target after Q1 results - Investing.com Australia
Refractive Surgery Market Is Booming So Rapidly 2025-2032 - openPR.com
Alcon up 4% as FDA approves Tryptyr drops for dry eye - MSN
Citi maintains Buy on Alcon, price target CHF99 after FDA nod - Investing.com Nigeria
Alcon gains FDA approval of Tryptyr in DED - The Pharma Letter
BTIG maintains Alcon $99 target, upbeat on TRYPTYR launch By Investing.com - Investing.com Canada
Citi maintains Buy on Alcon, price target CHF99 after FDA nod By Investing.com - Investing.com South Africa
FDA Approves Alcon’s Tryptyr for Dry Eye Disease - Managed Healthcare Executive
Alcon Secures First FDA Approval Since Novartis Spin-Off In 2019 - Benzinga
Alcon Stock Rises Following the FDA Approval of TRYPTYR - MSN
US FDA approves Alcon's new dry-eye drug - Reuters
FDA approves Alcon’s Tryptyr (AR-15512) for signs and symptoms of dry eye disease - Ophthalmology Times
Alcon receives FDA approval for Tryptyr to treat dry eye disease - World Pharmaceutical Frontiers
FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment By Investing.com - Investing.com South Africa
BTIG maintains Alcon $99 target, upbeat on TRYPTYR launch - Investing.com
Alcon’s Strategic Initiatives and Valuation Justify Buy Rating with $99 Price Target - TipRanks
US FDA Approves Alcon's Dry Eye Disease Treatment - marketscreener.com
US FDA approves Alcon’s new dry-eye drug - The Mighty 790 KFGO
Alcon (ALC) Gains FDA Approval for Innovative Dry Eye Treatment - GuruFocus
US FDA approves Alcon's new dry-eye drug (May 28) - marketscreener.com
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic s - GuruFocus
Alcon (ALC) Gains FDA Nod for Innovative Dry Eye Treatment | ALC Stock News - GuruFocus
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease | ALC Stock News - GuruFocus
FDA approves Alcon’s TRYPTYR for Dry Eye Disease treatment - Investing.com
Alcon Announces FDA Approval of TRYPTYR (acoltremon ophthalmic solution) 0.003% for the Treatment of the Signs and Symptoms of Dry Eye Disease - marketscreener.com
Gordon Schanzlin New Vision Institute First in Region to Offer Groundbreaking Alcon Sitemap Technology for Personalized Vision Correction - GlobeNewswire Inc.
BTIG maintains Alcon stock Buy rating, $99 target By Investing.com - Investing.com South Africa
DOJ Requires Keysight to Shed Spirent Units Before $1.57 Billion Acquisition Proceeds - PYMNTS.com
BTIG maintains Alcon stock Buy rating, $99 target - Investing.com
Alcon Inc (ALC) 財務データ
収益
当期純利益
現金流量
EPS
0.23%
大文字化:
|
ボリューム (24 時間):